Providers

An ecological study revealed increasing rates of skin cancer overdiagnosis in white Americans.

According to the authors, these improvements may be part of the reason why there was a lower rate of major adverse cardiovascular events in the REPRIEVE study.

The Mendelian randomization–based analysis, which examines how variation in genes have a causal effect of an exposure on certain outcomes, identified 12 gut microbiota associated with either an increased of or protective effect against MG.

A cross-sectional study analyzing morphological and dimensional features of palatal rugae patters revealed that distinct anomalies exist in children with sickle cell disease (SCD) compared with children without.

Quality Improvement (QI) projects require a series of distinct steps and timely data collection that will allow clinics to see if changes are yielding results, a consultant told attendees at a preconference workshop at ACCC.

Researchers of the review are underscoring the potential for economic policies to improve the management of hypertension for the millions of people throughout the United States with the condition who are at risk for cardiovascular disease.

In a recent presentation featured at the Midwest Business Group on Health's Mental Health Forum, an expert shed light on the evolving landscape shaped by the Mental Health Parity and Addiction Treatment Act.

At an Institute for Value-Based Medicine® event cohosted by The American Journal of Managed Care® and Optum, speakers emphasized that innovation is urgently needed in primary care delivery to address the broken US health care system.

The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) will host its ninth annual meeting in West Palm Beach, Florida, from February 29 to March 2, 2024, to address a plethora of barriers faced by patients and clinicians managing multiple sclerosis (MS).

Patrick Vermersch, MD, PhD, joined The American Journal of Managed Care® for an interview on promising data from a phase 2 clinical trial on frexalimab in the treatment of multiple sclerosis (MS) and associated neurodegeneration.

This week's news from the Center on Health Equity and Access discusses racial disparities in prostate cancer outcomes, the impact of access to cancer care on racial gaps in CLL/SLL outcomes, the effects of 340B programs on drug pricing and health care disparities, the role of mental illness in maternal mortality rates, and racial bias and diagnosis disparities in bipolar disorder.

Camilla Levister, MS, ANP-C, CDCES, a nurse practitioner at the Icahn School of Medicine at Mount Sinai Hospital in New York, gives insight into the nuances of testing closed-loop insulin delivery systems for pregnant women.

While adopting new payment models can come with challenges, there are strategies that can help oncology practices optimize their approaches, said Kathy Oubre, MS, CEO of Pontchartrain Cancer Center.

Patients with ovarian cancer living in rural areas reported less improvement in psychological function compared with patients living in urban areas in the year following ovarian cancer diagnosis.

In honor of Black History Month, Leesha Ellis-Cox, MD, MPH, sheds light on the racial disparities in mental health care and the prevalence of misdiagnosis.

Among patients with heart failure (HF), those taking dapaglifozin or empaglifozin had a 30% odds reduction in HF hospitalization, 14% odds reduction in cardiovascular mortality, and a 10% odds reduction in all-cause mortality compared with patients taking placebo.

Investigators say a better understanding of risk factors and categories can help personalize care for patients living with myelodysplastic syndrome (MDS).

A meta-analysis on complement inhibitors in the management of paroxysmal nocturnal hemoglobinuria (PNH) reveals an association between these interventions and positive treatment outcomes.

Outside of genetics, which has a well-documented link to the risk of type 1 diabetes (T1D), investigators detail available research spanning a variety of factors, including viral infections, pesticide exposure, and the gut microbiome.

Results of a phase 1/2 trial show encouraging outcomes for patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) treated with the fully oral regimen of venetoclax and decitabine plus cedazuridine.

Strengthening parity in insurance coverage of mental and physical health care benefits is critical for addressing the maternal mental health crisis.

Patients with early-stage hepatocellular carcinoma (HCC) and those with advanced-stage disease exhibited distinct gut microbiota diversity and alterations, with future studies warranted to investigate the mechanisms underlying the interactions between gut microbiota and HCC progression.

Andrew Ress, MD, discusses the novel integration of artificial intelligence (AI) into the skin cancer treatment landscape.

A bidirectional Mendelian randomization (MR) study found a casual relationship between sleep-related phenotypes (SRPs) and gut microbiota.

A meta-analysis of 3 case-controlled MS studies showed an association between susceptibility to multiple sclerosis (MS) and the vitamin D pathway.

Despite socioeconomic and biological differences that contribute to disparities between Black men and White men with prostate cancer, improved access has been shown to reduce the gaps, explained Jun Gong, MD, of Cedars Sinai.

Researchers said these findings confirm that zilebesiran can significantly reduce serum angiotensinogen levels, leading to sustained reductions in blood pressure over a 24-hour period, even 6 months post-treatment, though more research is needed for longer-term use.

Using home insulin pumps when hospitalized was relatively safe compared with hospital-managed pumps and insulin injections among more than 2700 children admitted to a single hospital center.

The retrospective study found patients on Bruton’s tyrosine kinase inhibitors are similar to the general population in the sense that it usually takes at least 2 anti-hypertensive drugs to control blood pressure.

Lifileucel was granted approval for the treatment of adults with unresectable or metastatic melanoma that has been previously treated with other therapies, marking the first approval of a tumor-derived cellular therapy in a solid tumor cancer.